Difference between revisions of "Part:BBa K4165156"

 
Line 5: Line 5:
 
Tau binding peptide targeting the PHF seed of Tau
 
Tau binding peptide targeting the PHF seed of Tau
  
−
<!-- Add more about the biology of this part here
 
 
===Usage and Biology===
 
===Usage and Biology===
 +
 +
The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively).
  
 
<!-- -->
 
<!-- -->
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4165156 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165156 SequenceAndFeatures</partinfo>
 +
 +
===Dry Lab===
 +
 +
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 +
MM2 is modeled by AlphaFold2, ITASSER and TrRosetta, best model obtained from TrRosetta.
 +
 +
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2.png" style="margin-left:200px;" alt="" width="300" /></p>
 +
</html>
 +
 +
                            Figure 1.: Predicted 3D structure of Synthetic peptide MM2.
 +
 +
 +
 +
<p style=" font-weight: bold; font-size:13px;"> Table 1: Quality assessment parameters of MM2 model. </p>
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm2-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 +
</html>
 +
 +
 +
===References===
 +
1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).
  
  

Revision as of 18:58, 5 October 2022


MM2 Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

The amino acid sequence of the MM2 peptide is LTPHKHHKHLHA. Its charge is +2.5, hydrophobicity is 33 %, molecular weight is 1455.67 Da. MM2 can reduce tau aggregates of full-length tau but not PHF* or PHF (VQIINK and VQIVYK respectively).

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

MM2 is modeled by AlphaFold2, ITASSER and TrRosetta, best model obtained from TrRosetta. 


                            Figure 1.: Predicted 3D structure of Synthetic peptide MM2.


Table 1: Quality assessment parameters of MM2 model.


References

1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).